KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $23.7 million.

  • Ionis Pharmaceuticals' Interest & Investment Income fell 970.72% to $23.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.9 million, marking a year-over-year decrease of 178.42%. This contributed to the annual value of $107.0 million for FY2024, which is 2019.41% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Interest & Investment Income of $23.7 million as of Q3 2025, which was down 970.72% from $24.7 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Interest & Investment Income high stood at $28.9 million for Q4 2024, and its period low was $872000.0 during Q3 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $20.8 million (2023), whereas its average is $16.0 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first tumbled by 8648.9% in 2021, then soared by 83462.12% in 2023.
  • Ionis Pharmaceuticals' Interest & Investment Income (Quarter) stood at $1.8 million in 2021, then skyrocketed by 557.3% to $11.9 million in 2022, then skyrocketed by 116.14% to $25.7 million in 2023, then increased by 12.55% to $28.9 million in 2024, then fell by 18.08% to $23.7 million in 2025.
  • Its Interest & Investment Income stands at $23.7 million for Q3 2025, versus $24.7 million for Q2 2025 and $24.7 million for Q1 2025.